Ocular Therapeutix insider filing reveals CCO’s 152.7k shares, 512k option grants
Rhea-AI Filing Summary
On 06/11/2025, Ocular Therapeutix (OCUL) Chief Commercial Officer Steve Lawrence Meyers filed a Form 3, establishing his initial beneficial ownership. He directly owns 152,728 common shares, including 117,317 unvested RSUs granted in 2023-2025 under the company’s 2021 Stock Incentive Plan. In addition, Meyers holds four option grants totaling 512,000 shares with strike prices ranging from $3.88 to $7.44 and expirations between 2032-2035; each option vests monthly over four years. The filing is routine, reflects no open-market purchases or sales, and does not alter the company’s capital structure.
Positive
- None.
Negative
- None.
Insights
TL;DR Form 3 shows CCO holds 152.7k shares and 512k options; administrative disclosure, no buy/sell action, neutral investor impact.
This Form 3 merely documents the equity position of a newly designated Section 16 officer. The disclosed holdings—roughly 0.2% of OCUL’s basic shares outstanding—align the CCO’s incentives with shareholders but do not represent a transaction or signal on valuation. All derivative securities are option grants from prior compensation plans, with strikes mostly above the recent trading range, so near-term dilution risk is negligible. Overall, the filing is non-material and should not influence valuation models or trading strategy.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Includes 11,111 restricted stock units ("RSUs") remaining unvested pursuant to an award of 33,333 RSUs granted under the 2021 Stock Incentive Plan, as amended (the "Plan"), of Ocular Therapeutix, Inc. (the "Corporation") on January 30, 2023; 32,206 RSUs remaining unvested pursuant to an award of 48,309 RSUs granted under the Plan on February 3, 2024; and 74,000 RSUs remaining unvested pursuant to an award of 74,000 RSUs granted under the Plan on February 11, 2025. Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the respective date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. This option was granted on April 4, 2022 and vests over four years, with 1/4 of the shares underlying the option having vested on March 15, 2023 and 1/48 of the shares vesting monthly thereafter. This option was granted on January 30, 2023 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date. This option was granted on February 3, 2024 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date. This option was granted on February 11, 2025 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
